Canada moves to limit prescription drug exports after Trump order

A new order in Canada prohibits bulk exportation of certain medications in cases in which a domestic shortage would be created. Canadian Health Minister Patty Hajdu explained, “Certain drugs intended for the Canadian market are prohibited from being distributed for consumption outside of Canada if that sale would cause or worsen a drug shortage. Companies will now also be required to provide information to assess existing or potential shortages, when requested, and within 24 hours if there is a serious or imminent health risk.” The order, which took effect on November 27, responds to a move by the Trump administration to allow Americans to import some prescription drugs. A major U.S. pharmaceutical lobbying group is suing to end the rule, asserting it violates the Federal Food, Drug and Cosmetic Act. “It is particularly disturbing that the administration is punting the responsibility for demonstrating safety and cost savings to state governments despite the clear requirement under federal law that the Secretary of HHS must certify that imported drugs both pose no additional risk to public safety and will lead to significant savings for the American consumer,” said James Stansel, general counsel for the Pharmaceutical Research and Manufacturers of America.